US drug companies lose 5% to 27% in profits if direct-to-consumer ads are banned

A new economic model shows what happens if the US banned direct-to-consumer drug advertising — something only the US and New Zealand allow among wealthy nations. Drug companies would cut spending on doctor detailing too, and profits would fall across all markets tested, from barely noticeable in ulcer drugs to more than a quarter in asthma medications.

This paper puts a number on something regulators have assumed but never measured: direct-to-consumer advertising and doctor-targeted marketing reinforce each other. Banning one without the other creates a gap that actually hurts company revenue more than banning both together would. The finding matters because every other developed country has banned direct-to-consumer ads without crashing the pharmaceutical business — this model suggests why the US pharmaceutical industry argues so hard against following them. It also shows that the cost of a ban isn't evenly distributed: some drug markets would barely notice, others would face significant restructuring.